Early and persisting response to vismodegib in a patient with bone metastasizing medulloblastoma

Acta Oncologica

Volumn 52, Issue 4, 2013, Pages 862-865

  Asklund, Thomas ^a   Henriksson, Roger ^a   Axelsson, Jan ^a   Bergström, Åsa ^b   Kasper, Maria ^b   Ögren, Margareta ^a   Toftgård, Rune ^b   Riklund, Katrine Åhlström ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; BETAMETHASONE; CARBOPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; GABAPENTIN; KETAMINE; METHADONE; METHOTREXATE; MORPHINE; TEMOZOLOMIDE; VINCRISTINE; VISMODEGIB; 3' FLUOROTHYMIDINE F 18; ANALGESIC AGENT; BENZODIAZEPINE DERIVATIVE;

ADULT; BONE MARROW BIOPSY; BONE METASTASIS; CASE REPORT; CRANIOSPINAL IRRADIATION; ERYTHROCYTE TRANSFUSION; EXTRAMEDULLARY HEMATOPOIESIS; HUMAN; LETTER; MALE; MEDULLOBLASTOMA; MUSCULOSKELETAL PAIN; MYALGIA; PALLIATIVE THERAPY; PANCYTOPENIA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SEDATION; TRANSVERSE SINUS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; HUMAN TISSUE; PAIN; POSITRON EMISSION TOMOGRAPHY;

EID: 84875960871     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2012.724537     Document Type: Letter

References (22)

1. Spencer CD, Weiss R B, van Eys J, C ohen P, E dwards B. Medulloblastoma metastatic to the marrow. Report of four caseSand review of the literature. J Neurooncol 1984; 2: 223-35.
2. Mazloom A, Z angeneh AH, Paulino AC. P rognostic factorSafteRextraneural metastasis of medulloblastoma. Int J Radiat Oncol Biol Phys 2010; 78: 72-8.
3. Al-Halabi H, N anteLa, K lekner A, G uiot M C, A lbrechTs, Hauser P, et al. Preponderance of sonic hedgehog pathway activation characterizeSadult medulloblastoma. Acta Neuropathol 2011; 121: 229-39.
4. Remke M, H ielscher T, N orthcott PA, W itt H, R yzhova M, Wittmann A, et al. Adult medulloblastoma comprises three major molecular variants. J Clin Oncol 2011; 29: 2717-23.
5. Dlugosz AA, T alpaz M. F ollowing the hedgehog to new cancer therapies. N Engl J Med 2009; 361: 1202-5.
6. Rudin CM, H ann CL, Laterra J, Y auch RL, Callahan CA, Fu L, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009; 361: 1173-8.
7. Chalkidou A, Landau DB, O dell EW, C ornelius VR, O'Doherty MJ, Marsden PK. Correlation between Ki-67 immunohistochemistry and 18F-Fluorothymidine uptake in patients with cancer: A systematic review and meta-analysis. Eur J CanceRepub 2012 May 31.
8. Price SJ, Fryer TD, C leij MC, Dean AF, J oseph J, Salvador R, et al. Imaging regional variation of cellular proliferation in gliomas using 3'-deoxy-3'-[18F]fl uorothymidine positronemission tomography: An image-guided biopsy study. Clin Radiol 2009; 64: 52-63.
9. Backes H, U llrich R, N eumaier B, K racht L, W ienhard K, JacobSaH. Noninvasive quantification of 18F-FLT human brain PET for the assessment of tumour proliferation in patients with high-grade glioma. Eur J Nucl Med Mol Imaging 2009; 36: 1960-7.
10. AgooLa, S lart R H, T horp K K, G laudemanSaW, Cobben DC, Been LB, et al. Effect of radiotherapy and chemotherapy on bone marrow activity: A 18F-FLT-PETstudy. Nucl Med Commun 2011; 32: 17-22.
11. Vanderhoek M, Juckett M B, P erlman S B, N ickles R J, Jeraj R. Early assessment of treatment response in patients with AML using [(18)F]FLT PET imaging. Leuk Res 2011; 35: 310-6.
12. Cook G J. P ET and PET/CT imaging of skeletal metastases. Cancer Imaging 2010; 10: 1-8.
13. Withofs N, G rayet B, T ancredi T, R orive A, M ella C, Giacomelli F, et al. (1)(8)F-fl uoride PET/CT for assessing bone involvement in prostate and breast cancers. Nucl Med Commun 2011; 32: 168-76.
14. Iagaru A, M ittra E, D ick DW, G ambhir SS. P rospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/ CT, and (18)F FDG PET/CT for detection of skeletal metastases. Mol Imaging Biol 2012; 14: 252-9.
15. Kieran MW, T urner CD, Rubin JB, Chi SN, Zimmerman MA, Chordas C, et al. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol 2005; 27: 573-81.
16. Buchroithner J, Nuβbaumer K, P ichler S, W eis S. A ntiangiogenetic metronomic chemotherapy in an adult with recurrent medulloblastoma with spinal metastases: A case report. Mag Eur Med Oncol 2010; 3(Suppl 3): 25-7.
17. Kim CH. H omeostatiCand pathogenic extramedullary hematopoiesis. J Blood Med 2010; 1: 13-9.
18. Di Marcotullio L, F erretti E, De Smaele E, A rgenti B, Mincione C, Zazzeroni F, et al. REN(KCTD11) iSa suppressor of hedgehog signaling and is deleted in human medulloblastoma. Proc NatLacad Sci U SA 2004; 101: 10833-8.
19. Bar EE, Chaudhry A, Farah MH, E berhart CG. H edgehog signaling promotes medulloblastoma survival via Bc/II. Am J Pathol 2007; 170: 347-55.
20. L orusso P M, J imeno A, D y G, A djei A, B erlin J, Leichman L, et al. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. Clin Cancer Res 2011; 17: 5774-82.
21. LoRusso P M, R udin C M, Reddy J C, T ibes R, W eiss G J, Borad MJ, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 2011; 17: 2502-11.
22. Metcalfe C, De Sauvage FJ. H edgehog fi ghts back: Mechanisms of acquired resistance againsTsmoothened antagonists. Cancer Res 2011; 71: 5057-61.